The weight-loss jab Wegovy made its debut on June 4 2021 . It was the first new weight-loss drug to be approved by the US ...

AC Immune SA (ACIU) has released an update. AC Immune SA announced promising interim results from its Phase 2 trial of the ACI-7104.056 ...

AC Immune (ACIU) stock shot up 20% Thursday after the company reported positive data from a Phase 2 study of its drug ...

Researchers are using functionalized nanodiamonds to precisely monitor neuronal activity at the cellular level, enhancing ...

As a result of his extraordinary life, items associated with President Kennedy command a high price when they are put up for ...

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein ...

reinforces the best-in-class characteristics of our clinically validated anti-a-syn active immunotherapy for the treatment of ...

With rising demand and an ageing population, European healthcare systems are under strain. In the second article in our ...

Numerous private clinics claim to offer miraculous cures for hard-to-treat medical conditions, even though their treatments are not based on sound science.

Researchers have identified a protein, TMEM16F, that appears to aid the spread of Parkinson’s pathology in the brain.

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.